Sanofi Shares Fall 2.77% at Close, Approaching Major Technical Support
Sanofi shares closed at 77.54 euros this Wednesday, January 28, 2026, down 2.77% from the previous session. The pharmaceutical stock is now down 23.49% over one year and 12.02% over the last three months.
Sanofi's stock price stands at 77.54 euros, very close to the major support level identified at 77.52 euros. The stock is also trading below the lower Bollinger band set at 77.71 euros, a configuration that in technical analysis terms suggests an extension of the downward movement beyond the usual statistical range. The 20-session moving average is at 81.18 euros, placing the current price 4.48% below this short-term trend indicator. The 14-period Relative Strength Index (RSI) is at 40, which is considered neutral territory, between the oversold zone (30) and the median zone (50).
Neutral Rating Reaffirmed by Citigroup
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Citigroup reaffirmed its neutral rating on the stock on January 27, 2026, with a target price set at 85.00 euros. This target is 9.62% above the current price. The company will publish its fourth-quarter results on Thursday, January 29, 2026. Future financial deadlines are scheduled for April 23, 2026 (first-quarter results), July 30, 2026 (semi-annual results), and October 30, 2026 (third-quarter results).
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 2025
Key reported figures
Revenue: 43 626 millions d'euros
Revenue growth: 9,9 %
Net income: 9 555 millions d'euros
Free cash flow: 8 089 millions d'euros
11 008 millions d'euros
Dividend per share: 4,12 €
Outlook / guidance
Expected revenue: Le chiffre d'affaires 2026 devrait croître à un chiffre élevé à taux de change constants.
Management commentary: Pour 2026, Sanofi anticipe une croissance solide et rentable et prévoit un programme de rachat d'actions d'un montant d'un milliard d'euros en 2026; un dividende de 4,12 euros est proposé.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
